Select Bibliography

Filter by any of these (after searching):

Holstein, Sarah

There are 11 items

Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM) CALGB 100104 (Alliance)

Ailawadhi, Sikander , McCarthy, Philip L. , Holstein, Sarah A. ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original - Meta-Analysis - Transplant - CALGB-100104 , E4A03 , MM-002 , MM-009

Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS) CALGB 100104 (Alliance)

Attal, Michel , Palumbo, Antonio , Holstein, Sarah ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma

Holstein, Sarah A. , Jung, Sin-Ho , Richardson, Paul G. ... - - Lancet Haematol - 2017

Manuscript - Primary - Long-Term-Followup - Myeloma - CALGB-100104

Updated analysis of CALGB 100104: lenalidomide (Len) vs. placebo maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM).

Holstein, Sarah A. , Owzar, Kouros , Richardson, Paul G. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary - Long-Term-Followup - Myeloma - CALGB-100104

Long-term follow-up of CALGB (Alliance) 100001: Autologous followed by non-myeloablative allogeneic transplant for multiple myeloma

Holstein, Sarah A. , Suman, Vera J. , Owzar, Kouros , Santo, Katelyn ... - - Biol. Blood Marrow Transplant. - 2020

Manuscript - Primary - Long-Term-Followup - Myeloma - CALGB-100001

CALGB/ECOG 100104 (Alliance) Study: Lenalidomide (LEN) vs Placebo (PBO) Maintenance (Maint) After Stem Cell Transplant (SCT) for Patients (Pts) With Multiple Myeloma: Overall Survival (OS) and Progression-Free Survival (PFS) Adjusted for Treatment (Tx) Crossover (XO)

McCarthy, Philip L. , Holstein, Sarah A. , Jung, Sin-Ho ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

Overall and Progression-Free Survival Adjusted for Treatment Crossover in the CALGB 100104 Study of Lenalidomide Versus Placebo Maintenance After Stem Cell Transplant for Patients With Newly Diagnosed Multiple Myeloma (Alliance)

McCarthy, Philip L. , Holstein, Sarah A. , Jung, Sin-Ho ... - IMW - - 2017

Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

Lenalidomide vs Placebo Maintenance After Stem Cell Transplant for Patients With Multiple Myeloma: Overall Survival and Progression-Free Survival After Adjusting for Treatment Crossover in CALGB

McCarthy, Philip L. , Holstein, Sarah A. , Jung, Sin-Ho ... - EHA - Haematologica - 2017

Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

McCarthy, Philip L. , Holstein, Sarah A. , Petrucci, Maria Teresa ... - - J. Clin. Oncol - 2017

Manuscript - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

Survival analysis from the CALGB trial of lenalidomide (LEN) maintenance therapy in newly diagnosed multiple myeloma (NDMM) post-autologous stem cell transplant (ASCT), adjusting for crossover (Alliance)

McCarthy, Philip L. , Suman, Vera , Cooper, Miranda , Saunders, Owain ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.

Voorhees, Peter M , Kaufman, Jonathan L , Laubach, Jacob ... - - Blood - 2020

Manuscript - Primary - Primary - Myeloma - AFT-29